Home > Publications Database > Astroglial glucose uptake determines brain FDG-PET alterations and metabolic connectivity during healthy aging in mice > print

001     272510
005     20250127091513.0
024 7 _ |a pmid:39332748
|2 pmid
024 7 _ |a 10.1016/j.neuroimage.2024.120860
|2 doi
024 7 _ |a 1053-8119
|2 ISSN
024 7 _ |a 1095-9572
|2 ISSN
037 _ _ |a DZNE-2024-01186
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Bartos, Laura M.
|0 0009-0007-6158-319X
|b 0
245 _ _ |a Astroglial glucose uptake determines brain FDG-PET alterations and metabolic connectivity during healthy aging in mice
260 _ _ |a Orlando, Fla.
|c 2024
|b Academic Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1729167842_2186
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a 2-Fluorodeoxyglucose-PET (FDG-PET) is a powerful tool to study glucose metabolism in mammalian brains, but cellular sources of glucose uptake and metabolic connectivity during aging are not yet understood.Healthy wild-type mice of both sexes (2-21 months of age) received FDG-PET and cell sorting after in vivo tracer injection (scRadiotracing). FDG uptake per cell was quantified in isolated microglia, astrocytes and neurons. Cerebral FDG uptake and metabolic connectivity were determined by PET. A subset of mice received measurement of blood glucose levels to study associations with cellular FDG uptake during aging.Cerebral FDG-PET signals in healthy mice increased linearly with age. Cellular FDG uptake of neurons increased between 2 and 12 months of age, followed by a strong decrease towards late ages. Contrarily, FDG uptake in microglia and astrocytes exhibited a U-shaped function with respect to age, comprising the predominant cellular source of higher cerebral FDG uptake in the later stages. Metabolic connectivity was closely associated with the ratio of glucose uptake in astroglial cells relative to neurons. Cellular FDG uptake was not associated with blood glucose levels and increasing FDG brain uptake as a function of age was still observed after adjusting for blood glucose levels.Trajectories of astroglial glucose uptake drive brain FDG-PET alterations and metabolic connectivity during aging.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 7 |a Aging
|2 Other
650 _ 7 |a Astroglia
|2 Other
650 _ 7 |a FDG-PET
|2 Other
650 _ 7 |a Metabolic connectivity
|2 Other
650 _ 7 |a Scradiotracing
|2 Other
650 _ 7 |a Fluorodeoxyglucose F18
|0 0Z5B2CJX4D
|2 NLM Chemicals
650 _ 7 |a Glucose
|0 IY9XDZ35W2
|2 NLM Chemicals
650 _ 7 |a Radiopharmaceuticals
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Fluorodeoxyglucose F18: pharmacokinetics
|2 MeSH
650 _ 2 |a Astrocytes: metabolism
|2 MeSH
650 _ 2 |a Positron-Emission Tomography: methods
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Glucose: metabolism
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Mice, Inbred C57BL
|2 MeSH
650 _ 2 |a Aging: metabolism
|2 MeSH
650 _ 2 |a Radiopharmaceuticals: pharmacokinetics
|2 MeSH
650 _ 2 |a Neurons: metabolism
|2 MeSH
650 _ 2 |a Healthy Aging: metabolism
|2 MeSH
650 _ 2 |a Microglia: metabolism
|2 MeSH
700 1 _ |a Kunte, Sebastian T.
|b 1
700 1 _ |a Wagner, Stephan
|b 2
700 1 _ |a Beumers, Philipp
|b 3
700 1 _ |a Schaefer, Rebecca
|0 0009-0006-7218-0591
|b 4
700 1 _ |a Zatcepin, Artem
|0 P:(DE-2719)9001654
|b 5
700 1 _ |a Li, Yunlei
|0 P:(DE-2719)9002722
|b 6
|u dzne
700 1 _ |a Griessl, Maria
|b 7
700 1 _ |a Hoermann, Leonie
|b 8
700 1 _ |a Wind-Mark, Karin
|0 P:(DE-2719)9001653
|b 9
|u dzne
700 1 _ |a Bartenstein, Peter
|b 10
700 1 _ |a Tahirovic, Sabina
|0 P:(DE-2719)2442036
|b 11
|u dzne
700 1 _ |a Ziegler, Sibylle
|b 12
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 13
700 1 _ |a Gnörich, Johannes
|0 P:(DE-2719)9001652
|b 14
|e Last author
773 _ _ |a 10.1016/j.neuroimage.2024.120860
|g Vol. 300, p. 120860 -
|0 PERI:(DE-600)1471418-8
|p 120860
|t NeuroImage
|v 300
|y 2024
|x 1053-8119
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/272510/files/DZNE-2024-01186.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/272510/files/DZNE-2024-01186.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:272510
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9001654
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 6
|6 P:(DE-2719)9002722
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)9001653
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2442036
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)9001539
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)9001652
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROIMAGE : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T08:47:40Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T08:47:40Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROIMAGE : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1140003
|k AG Tahirovic
|l Juvenile Neurodegeneration
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a I:(DE-2719)1140003
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21